Back to News
Market Impact: 0.3
Sagimet Biosciences Inc. Announces Clinical Updates for Denifanstat and TVB-3567
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Sagimet Biosciences said the first patient was dosed in October 2026 in the U.S. AURORA Phase 3 trial of denifanstat for moderate-to-severe acne. The company also announced clinical updates for denifanstat and follow-on candidate TVB-3567, but the provided article text ends before further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
SGMT0.45
More News
- SK Hynix shares slide after chipmaker scraps Solidigm IPO plans
- Apple’s iPhone Duo Hits Stores in Face of Short Supply and High Demand
- OpenAI nears up to $30 billion funding round at $1.25 trillion valuation led by UAE investors
- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
- Moderna shares plunge after leak of partial cancer vaccine data
- SpaceX records $561 million investment gain from stake in Elon Musk's Boring Co.
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Sector Analysis, Improvements on Research Data, and Performance Enhancements
- Choosing an AI Copilot for Equity Research